FULCRUM THERAPEUTICS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- FULCRUM THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2023-03-31 was $117.35M.
- FULCRUM THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2021-09-30 was $135.45M, a 150401.11% increase year-over-year.
- FULCRUM THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2021-03-31 was $47.41M, a 16247.24% increase year-over-year.
- FULCRUM THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2020-09-30 was $90.00K, a 157.14% increase year-over-year.
- FULCRUM THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2023 was $117.35M, a 45.22% increase from fiscal 2022.
- FULCRUM THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2022 was $80.80M, a 55.81% decline from fiscal 2021.
- FULCRUM THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2021 was $182.86M.
- FULCRUM THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2019 was $268.00K, a 1016.67% increase from fiscal 2018.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | $164.17M S-4 · filed 2026-09-02 | |
| 2023-12-31 | $117.35M 10-K · filed 2025-02-25 | |
| 2023-03-31 | $117.35M 10-Q · filed 2024-11-13 | |
| 2022-12-31 | $80.80M 10-K · filed 2024-02-27 | |
| 2021-12-31 | $182.86M 10-K/A · filed 2023-06-26 | |
| 2021-09-30 | $135.45M 10-Q · filed 2021-11-04 | |
| 2021-03-31 | $47.41M 10-Q · filed 2021-11-04 | |
| 2020-09-30 | $90.00K 10-Q · filed 2020-11-10 | |
| 2020-06-30 | $530.00K 10-Q · filed 2020-11-10 | |
| 2020-03-31 | $290.00K 10-Q · filed 2020-11-10 | |
| 2019-12-31 | $268.00K 10-K · filed 2020-03-05 | |
| 2019-09-30 | $35.00K 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $225.00K 10-Q · filed 2020-11-10 | |
| 2019-03-31 | $5.00K 10-Q · filed 2020-11-10 | |
| 2018-12-31 | $24.00K 10-K · filed 2020-03-05 | |
| 2018-09-30 | $5.00K 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $8.00K 10-Q · filed 2019-11-14 | |
| 2018-03-31 | $4.00K 10-Q · filed 2019-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |